Literature DB >> 18211257

Population-based standardization (PBS) of institutional cesarean delivery rates.

Amos Grünebaum1, Frank Chervenak, Daniel Skupski.   

Abstract

BACKGROUND: Raw cesarean section rates are often compared among institutions with different patient populations. The purpose of this study was to develop an easily reproducible mathematical model that allows comparisons of cesarean delivery rates across different patient populations and institutions. STUDY
DESIGN: We first calculated three institution's cesarean delivery rates for each of ten groups of patients based on age and parity. The population based adjusted total cesarean delivery rate was then calculated for each institution based on the distribution of patients in the 2004 national birth data (n=4,097,029) but using the three institutions' individual cesarean delivery rates.
RESULTS: The adjusted for age and parity cesarean delivery rate was significantly lower from raw cesarean delivery rates in two of the three institutions (A: 28.2% adjusted vs. 36.5% raw; P=0; B: 28.2% adjusted vs. 30.4% raw, P=0.0411; C: 28.7% adjusted vs. 29.7% raw, NS) reflecting the older and more nulliparous patients in these two institutions.
CONCLUSIONS: Our study confirms that raw cesarean delivery rate should not be used to compare quality of care within and among different institutions unless they are adjusted for different patient characteristics. We believe that using unadjusted cesarean delivery rates without appropriate adjustments in quality assurance and when comparing data with other institutions and the national rate is erroneous and misleading.

Entities:  

Mesh:

Year:  2008        PMID: 18211257     DOI: 10.1515/JPM.2008.026

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  1 in total

1.  A global reference for caesarean section rates (C-Model): a multicountry cross-sectional study.

Authors:  J P Souza; A P Betran; A Dumont; B de Mucio; C M Gibbs Pickens; C Deneux-Tharaux; E Ortiz-Panozo; E Sullivan; E Ota; G Togoobaatar; G Carroli; H Knight; J Zhang; J G Cecatti; J P Vogel; K Jayaratne; M C Leal; M Gissler; N Morisaki; N Lack; O T Oladapo; Ö Tunçalp; P Lumbiganon; R Mori; S Quintana; A D Costa Passos; A C Marcolin; A Zongo; B Blondel; B Hernández; C J Hogue; C Prunet; C Landman; C Ochir; C Cuesta; C Pileggi-Castro; D Walker; D Alves; E Abalos; Ecd Moises; E M Vieira; G Duarte; G Perdona; I Gurol-Urganci; K Takahiko; L Moscovici; L Campodonico; L Oliveira-Ciabati; M Laopaiboon; M Danansuriya; M Nakamura-Pereira; M L Costa; M R Torloni; M R Kramer; P Borges; P B Olkhanud; R Pérez-Cuevas; S B Agampodi; S Mittal; S Serruya; V Bataglia; Z Li; M Temmerman; A M Gülmezoglu
Journal:  BJOG       Date:  2015-08-10       Impact factor: 6.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.